Top-News

Genprex Aktie News

Aktie
WKN:  A41L3N ISIN:  US3724463027 US-Symbol:  GNPX Branche:  Biotechnologie Land:  USA
3,32 $
+0,08 $
+2,47%
2,8396 € 21:59:54 Uhr
Depot/Watchlist
Marktkapitalisierung *
4,76 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Genprex News

24.11.25 - PR Newswire
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer PR Newswire
19.11.25 - PR Newswire
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials PR Newswire
18.11.25 - PR Newswire
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers PR Newswire
04.11.25 - PR Newswire
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer PR Newswire
28.10.25 - PR Newswire
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-​The-Market Under Nasdaq Rules PR Newswire
28.10.25 - PR Newswire
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-​NCI-EORTC International ...
23.10.25 - PR Newswire
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-​The-Market Under Nasdaq Rules PR Newswire
14.10.25 - PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-​NCI-EROTC International ...
02.09.25 - PR Newswire
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences PR Newswire
18.08.25 - PR Newswire
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers PR Newswire
04.08.25 - PR Newswire
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update PR Newswire
24.06.25 - PR Newswire
Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions PR Newswire
23.06.25 - PR Newswire
Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions
Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association ...
03.06.25 - PR Newswire
Genprex to Participate at BIO 2025 International Convention
Genprex to Participate at BIO 2025 International Convention PR Newswire
29.05.25 - PR Newswire
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting PR Newswire
28.05.25 - PR Newswire
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting PR Newswire
07.05.25 - PR Newswire
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes PR Newswire
06.05.25 - PR Newswire
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma PR Newswire
30.04.25 - PR Newswire
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual ...
29.04.25 - PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting PR Newswire

Newssuche

Videos

newspaper
08.12.25 -2,99%
Technical Trading: Die besten 3 Tage
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

Abschluss!
Grande Portage Resources Ltd
0,218 €
+10,7%
Grande Portage Resources Ltd Chart
Sprott zieht durch - und der Markt sollte aufwachen!
Mehr zur Aktie »